Autonomix Appoints Jennifer Cook as Chief Business Officer
March 19 2024 - 8:45AM
Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the
“Company”), a medical device company focused on advancing
innovative technologies to revolutionize how diseases involving the
nervous system are diagnosed and treated, today announced the
appointment of Jennifer Cook as its Chief Business Officer.
Mrs. Cook is an innovative, cross-functional
leader with significant expertise working with early developmental
stage companies and building them into fully integrated companies.
Over the course of her career, she has a proven track record with
translating vision to expand value proposition and creating
successful go-to-market solutions. “We are very pleased to welcome
Jennifer to the Autonomix team. Her expertise in business strategy
and analysis will be of great value as we continue to execute on
our corporate and clinical efforts moving forward. Most notably, we
believe her demonstrated success within start-ups and medical
technology brands in establishing global positioning and
competitive brand strategy and go-to-market solutions make her the
ideal candidate to round off the expertise of our team and helping
to propel Autonomix to our next phase of growth,” commented Lori
Bisson, Chief Executive Officer of Autonomix.
“Autonomix has positioned itself as a compelling
opportunity and promising potential solution in the field of
electrophysiology. The groundbreaking technology supported by a
solid leadership team with successful track records has established
a solid foundation from which the Company can grow. I look forward
to working closely with the team to bolster the business strategy
and generate value in the near and long term for all stakeholders,”
added Mrs. Cook.
Mrs. Cook joins Autonomix having most recently
served as the Vice President of Marketing at MedShift, a technology
company helping to drive growth and scale to medical device
manufacturers and healthcare providers. Prior to MedShift, Mrs.
Cook served as the Vice President of Marketing at Soliton, Inc.
While at Soliton she was responsible for bringing forward-thinking
vision and leadership to craft the brand, commercial strategy and
commercial go-to-market plan that launched the novel cellulite and
tattoo removal medical aesthetic device RESONIC, which played a
pivotal role in Soliton being acquired by AbbVie for a $550 million
enterprise valuation. Prior to Soliton, Mrs. Cook was the Director
of Consumer Marketing and Marketing Communications at Apollo
Endosurgery, Inc. where she led patient positioning, segmentation,
research, advertising, and marketing operations for Apollo’s
portfolio of Class II medical devices, the LapBand and Orbera
Weight Loss Balloon. Other career appointments include Integrated
Marketing Director at Real Chemistry (formerly W2O Group); Vice
President at Stern Advertising; Account Director at Rosetta
Marketing (acquired by Publicis Groupe/Razorfish); and Brand
Account Director at Doner Advertising.
Mrs. Cook holds a Bachelor of Science in
Business Administration and Marketing from Miami University,
Oxford, Ohio.
About Autonomix Medical,
Inc.
Autonomix is a medical device company focused on
advancing innovative technologies to revolutionize how diseases
involving the nervous system are diagnosed and treated. The
Company’s first-in-class technology platform includes a
catheter-based microchip sensing array that has the ability to
detect and differentiate neural signals with approximately 3,000
times greater sensitivity than currently available technologies. We
believe this will enable, for the first time ever, transvascular
diagnosis and treatment of diseases involving the peripheral
nervous system virtually anywhere in the body.
We are initially developing our technology for
pancreatic cancer pain, a condition that can cause debilitating
pain and needs an effective solution. However, our technology
constitutes a platform with the potential to address dozens of
indications, including in cardiology, renal denervation and chronic
pain management across a wide disease spectrum.
For more information, visit autonomix.com and
connect with the Company on X, LinkedIn, Instagram and
Facebook.
Forward Looking Statements
Some of the statements in this release are
“forward-looking statements,” which involve risks and
uncertainties. Such forward-looking statements can be identified by
the use of words such as ‘should,’ ‘may,’ ‘intends,’ ‘anticipates,’
‘believes,’ ‘estimates,’ ‘projects,’ ‘forecasts,’ ‘expects,’
‘plans,’ and ‘proposes.’
Although Autonomix Medical, Inc. (or Autonomix)
believes that the expectations reflected in these forward-looking
statements are based on reasonable assumptions, there are a number
of risks and uncertainties that could cause actual results to
differ materially from such forward-looking statements. You are
urged to carefully review and consider any cautionary statements
and other disclosures, including the statements made under the
heading “Risk Factors” and elsewhere in the offering circular filed
with the U.S. Securities and Exchange Commission (“SEC”) on January
26, 2024. Forward-looking statements speak only as of the date of
the document in which they are contained and Autonomix does not
undertake any duty to update any forward-looking statements except
as may be required by law.
Investor and Media ContactJTC Team, LLCJenene
Thomas833-475-8247autonomix@jtcir.com
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From Apr 2024 to May 2024
Autonomix Medical (NASDAQ:AMIX)
Historical Stock Chart
From May 2023 to May 2024